Markets

Evotec expands research partnership – Biontech starts corona vaccine approval process

Biotechnology companies are in the focus of investors these days. While Biontech is developing a corona vaccine, Evotec has developed a therapy option against Alzheimer’s.

First things first about Biontech and Evotec:

  • Evotec expands cooperation with Bristol-Myers Squibb
  • Biontech’s corona drug in the approval process

The drug researcher Evotec and the pharmaceutical company Bristol-Myers Squibb are expanding their research partnership. As part of the alliance that has existed since 2016 to identify therapeutic options for neurodegenerative diseases, the partners have added a further approach with a view to Alzheimer’s disease in the portfolio, Evotec announced in a press release. In this context, the German company is reported to receive a payment of six million dollars.

According to the company, currently approved drugs only relieve symptoms in the short term and there is a high unmet medical need for therapy options that slow or reverse the progression of neurodegenerative diseases.

“Our joint portfolio is growing in breadth but – more importantly – in depth, as significant progress is being made in most projects,” said Cord Dohrmann, Chief Scientific Officer of Evotec. While target-based approaches repeatedly fail in clinical development, Evotec believes it is delivering a new generation of disease-relevant drug candidates for better defined patient groups.

The corona vaccine candidate developed by the Mainz immunotherapy company Biontech is entering the approval process. The European Medicines Agency EMA will examine the active ingredient BNT162b2 in a so-called rolling review process, announced Biontech and the pharmaceutical company Pfizer in a press release. In this process, data from the clinical trial is continuously submitted and evaluated. This rolling submission process should accelerate the approval of the vaccine.

This makes Biontech the first German company and, with AstraZeneca, the second overall to be approved by the EMA for this process. The EMA’s decision to begin the process is based on encouraging preliminary data from both preclinical and early clinical trials in adults. The formal application for marketing authorization could be finalized following the ongoing review.

According to the press release, the vaccine candidate will continue to be subject to the strict quality, safety and effectiveness standards of the EMA. “As we work to develop a potential vaccine at an unprecedented rate to end this pandemic, it is our duty to ensure that we do so with the highest ethical standards and in accordance with sound scientific principles” said Ugur Sahin, co-founder of Biontech, according to the announcement.

According to the company, the vaccine candidate is currently being investigated in an ongoing global phase 2/3 study. The study includes more than 120 study centers worldwide, including in the USA, Brazil, South Africa and Argentina. To date, the study has enrolled about 37,000 participants, of whom more than 28,000 received their second vaccination.

Products on BioNTech

When purchasing certificates and leverage products, investors should familiarize themselves with how they work and understand the opportunities and risks. Investors should be particularly aware of the increased risks associated with leverage products. In addition, it is essential to pay attention to the creditworthiness and thus to the risk of default of the issuer. You can obtain further important and useful information about our products by calling the toll-free number 0800 4000 910 or on our website www.hsbc-zertifikate.de.

Source: HSBC

Click here for the HSBC homepage

Are you interested in a daily delivery of our newsletter?

Subscribe for free

Important instructions

This document was created by HSBC Trinkaus & Burkhardt AG (“HSBC”). It is for informational purposes only and may not be passed on to third parties without the express written consent of HSBC. The document is a marketing tool. The legal requirements for the impartiality of financial analyzes are not met. There is no ban on trading the financial products discussed before this presentation is published (“front running”). The document is also not a substitute for expert investment advice tailored to individual requirements. A subscription offer is also not yet associated with this. The document is only aimed at people who have their permanent residence / seat in Germany or Austria. It is not intended for recipients in other jurisdictions, and especially not for US citizens. Any information given on historical performance (including simulations) and forecasts of future performance of the financial products / financial indices presented are not a reliable indicator of future performance. If the financial products discussed are listed in a currency other than EUR, the return may rise or fall due to currency fluctuations. The tax treatment of an investment depends on the personal circumstances of the investor and can be subject to future changes. The information given in this document is based on sources which we believe to be reliable, but which we have not subjected to impartial testing. We do not guarantee and accept no liability for the correctness and completeness of the information contained herein.

Advertising notice

The basic prospectuses as well as the final terms and the basic information sheets are available here. By entering the respective WKN in the search field or via the “Products” tab, you can access the individual product view. There, under “Downloads”, the relevant final terms and conditions for the individual products can be called up, which contain the terms and conditions of the offer, including the relevant terms and conditions, as well as the relevant basic information sheets.

The approval of the base prospectus by the BaFin is not to be understood as its approval of the securities offered. We recommend that interested parties and potential investors read the Base Prospectus and the Final Terms before making an investment decision in order to obtain as much information as possible, in particular about the potential risks and opportunities of the security.

You are about to acquire a product that is not easy and can be difficult to understand.

License notice

“DAX®”, “TecDAX®”, “MDAX®”, “VDAX-NEW®”, “SDAX®”, “DivDAX®”, “ÖkoDAX®”, “Entry Standard Index”, “X-DAX®” and “GEX®” are the intellectual property (including registered trademarks) of Deutsche Börse AG (“DBAG”), Deutsche Börse Group or their licensors and are used under license. The securities are neither promoted, advertised, distributed or supported in any other way by DBAG, Deutsche Börse Group or their licensors, research partners or data suppliers, and DBAG, Deutsche Börse Group and their licensors, research partners or data suppliers assume no warranty and exclude any guarantee Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.

EURO STOXX 50®, STOXX 50®, STOXX® 600 and its brands, STOXX® Europe 600 Oil & Gas, STOXX® Europe 600 Basic Resources, EURO STOXX 50® DVP are the intellectual property (including registered trademarks) of STOXX Ltd., Zug, Switzerland (“STOXX”), Deutsche Börse Group or its licensors and is used under license. The securities are neither promoted, advertised, distributed or supported in any other way by STOXX, Deutsche Börse Group or their licensors, research partners or data suppliers, and STOXX, Deutsche Börse Group and its licensors, research partners or data suppliers assume no warranty and exclude any guarantee Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.

The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s®, S & P® and S&P 500® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representations as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the S&P 500 Index.

Nasdaq® and Nasdaq-100 Index® are registered trademarks of Nasdaq, Inc. (together with its affiliated companies referred to as the “Companies”) and are licensed to HSBC Trinkaus & Burkhardt AG for use by them. The companies make no statements about the legality or suitability of the securities. The companies do not issue, recommend, sell or advertise the securities. THE COMPANIES MAKE NO WARRANTIES AND ASSUME NO LIABILITY IN CONNECTION WITH THE SECURITIES.

The “Dow Jones Industrial Average” is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s® and S & P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and DJIA®, The Dow®, Dow Jones® and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or advertised by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representations as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the Dow Jones Industrial Average.

Publisher: HSBC Trinkaus & Burkhardt AG, Königsallee 21/23, 40212 Düsseldorf

Tags

Related Articles

Back to top button
Close
Close